Stocktoria
Mereo BioPharma Group plc MREO
Mereo BioPharma Group plc financials (annual)
Bars are annual figures from 2022 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $500,000 | $0 | $10.0M | $0 |
| R&D expense | $17.8M | $20.9M | $17.4M | $29.5M |
| Operating income | -$40.1M | -$47.4M | -$28.4M | -$54.4M |
| Interest expense | $255,000 | $1.4M | $2.9M | $4.2M |
| Income tax | $0 | $0 | -$532,000 | -$718,000 |
| Net income | -$41.9M | -$43.3M | -$29.5M | -$42.2M |
| EPS (diluted) | $-0.05 | $-0.06 | $-0.04 | $-0.07 |
| Operating cash flow | -$31.0M | -$32.8M | -$21.1M | -$48.8M |
| Free cash flow | -$31.0M | -$32.8M | -$21.1M | -$48.8M |
| Cash & equivalents | $41.0M | $69.8M | $57.4M | $68.2M |
| Total assets | $45.9M | $76.4M | $66.5M | $77.4M |
| Total liabilities | $5.0M | $15.4M | $16.0M | $26.0M |
| Shareholders' equity | $40.9M | $61.0M | $50.5M | $51.4M |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue growth | — | -100.0% | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.